{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T13:10:30Z","timestamp":1785157830964,"version":"3.55.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:00:00Z","timestamp":1672876800000},"content-version":"vor","delay-in-days":369,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007703","name":"NC State University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007703","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.ymthe.2021.08.009","type":"journal-article","created":{"date-parts":[[2021,8,8]],"date-time":"2021-08-08T04:59:24Z","timestamp":1628398764000},"page":"295-310","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Targeting KIT by frameshifting mRNA transcripts as a therapeutic strategy for aggressive mast cell neoplasms"],"prefix":"10.1016","volume":"30","author":[{"given":"Douglas B.","family":"Snider","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greer K.","family":"Arthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido H.","family":"Falduto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Olivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren C.","family":"Ehrhardt-Humbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmaline","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cierra","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean D.","family":"Metcalfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Cruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2021.08.009_bib1","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/onc.2010.494","article-title":"Tumor-intrinsic and -extrinsic roles of c-Kit: Mast cells as the primary off-target of tyrosine kinase inhibitors","volume":"30","author":"Pittoni","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.ymthe.2021.08.009_bib2","doi-asserted-by":"crossref","first-page":"6382","DOI":"10.1073\/pnas.88.14.6382","article-title":"Induction of mast cell proliferation, maturation, and heparin synthesis by the rat c-kit ligand, stem cell factor","volume":"88","author":"Tsai","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2021.08.009_bib3","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.4049\/jimmunol.151.7.3775","article-title":"IL-3-dependent murine mast cells undergo apoptosis on removal of IL-3. Prevention of apoptosis by c-kit ligand","volume":"151","author":"Mekori","year":"1993","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2021.08.009_bib4","first-page":"321","article-title":"The c-kit ligand, stem cell factor, promotes mast cell survival by suppressing apoptosis","volume":"144","author":"Iemura","year":"1994","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ymthe.2021.08.009_bib5","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000236928","article-title":"Regulation of mouse and human mast cell development, survival and function by stem cell factor, the ligand for the c-kit receptor","volume":"107","author":"Galli","year":"1995","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.ymthe.2021.08.009_bib6","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/320415a0","article-title":"A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family","volume":"320","author":"Besmer","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2021.08.009_bib7","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.iac.2014.01.002","article-title":"Functional deregulation of KIT: Link to mast cell proliferative diseases and other neoplasms","volume":"34","author":"Cruse","year":"2014","journal-title":"Immunol. Allergy Clin. North Am."},{"key":"10.1016\/j.ymthe.2021.08.009_bib8","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1158\/0008-5472.CAN-16-2234","article-title":"Advances in the classification and treatment of mastocytosis: Current status and outlook toward the future","volume":"77","author":"Valent","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2021.08.009_bib9","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1182\/blood-2005-07-3022","article-title":"PKC412 inhibits in\u00a0vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects","volume":"107","author":"Gleixner","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2021.08.009_bib10","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2021.08.009_bib11","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1038\/bjp.2008.204","article-title":"Pharmacological targeting of the KIT growth factor receptor: A therapeutic consideration for mast cell disorders","volume":"154","author":"Jensen","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ymthe.2021.08.009_bib12","first-page":"2207","article-title":"Organization and nucleotide sequence of the human KIT (mast\/stem cell growth factor receptor) proto-oncogene","volume":"7","author":"Giebel","year":"1992","journal-title":"Oncogene"},{"key":"10.1016\/j.ymthe.2021.08.009_bib13","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/leu.2015.24","article-title":"KIT mutation analysis in mast cell neoplasms: Recommendations of the European Competence Network on Mastocytosis","volume":"29","author":"Arock","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2021.08.009_bib14","first-page":"4297","article-title":"Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors","volume":"59","author":"Taniguchi","year":"1999","journal-title":"Cancer Res."},{"issue":"Suppl 5","key":"10.1016\/j.ymthe.2021.08.009_bib15","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S0959-8049(02)80602-5","article-title":"Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): A review","volume":"38","author":"Miettinen","year":"2002","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ymthe.2021.08.009_bib16","doi-asserted-by":"crossref","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","article-title":"Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder","volume":"92","author":"Nagata","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2021.08.009_bib17","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","article-title":"KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients","volume":"108","author":"Garcia-Montero","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2021.08.009_bib18","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood.V99.5.1741","article-title":"The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations","volume":"99","author":"Ma","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2021.08.009_bib19","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(03)14115-3","article-title":"Imatinib for systemic mast-cell disease","volume":"362","author":"Pardanani","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2021.08.009_bib20","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41375-019-0450-8","article-title":"Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis","volume":"33","author":"L\u00fcbke","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2021.08.009_bib21","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1089\/hum.2015.070","article-title":"Oligonucleotide therapies: The past and the present","volume":"26","author":"Lundin","year":"2015","journal-title":"Hum. Gene Ther."},{"issue":"6, Suppl","key":"10.1016\/j.ymthe.2021.08.009_bib22","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1097\/IAE.0b013e3181ad2341","article-title":"Combination therapy using the small interfering RNA bevasiranib","volume":"29","author":"Singerman","year":"2009","journal-title":"Retina"},{"key":"10.1016\/j.ymthe.2021.08.009_bib23","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.jaci.2015.12.1344","article-title":"Antisense molecules: A new class of drugs","volume":"137","author":"Potaczek","year":"2016","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"key":"10.1016\/j.ymthe.2021.08.009_bib24","doi-asserted-by":"crossref","first-page":"100416","DOI":"10.1016\/j.jbc.2021.100416","article-title":"Antisense technology: A review","volume":"296","author":"Crooke","year":"2021","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2021.08.009_bib25","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41573-021-00162-z","article-title":"Antisense technology: An overview and prospectus","volume":"20","author":"Crooke","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2021.08.009_bib26","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jconrel.2021.03.043","article-title":"The dawn of mRNA vaccines: The COVID-19 case","volume":"333","author":"Verbeke","year":"2021","journal-title":"J.\u00a0Control. Release"},{"key":"10.1016\/j.ymthe.2021.08.009_bib27","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40265-021-01480-7","article-title":"BNT162b2 mRNA COVID-19 vaccine: First approval","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2021.08.009_bib28","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.1093\/nar\/gkw533","article-title":"Splice-switching antisense oligonucleotides as therapeutic drugs","volume":"44","author":"Havens","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2021.08.009_bib29","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.toxrep.2015.05.008","article-title":"The use of urinary and kidney SILAM proteomics to monitor kidney response to high dose morpholino oligonucleotides in the mdx mouse","volume":"2","author":"Zhang","year":"2015","journal-title":"Toxicol. Rep."},{"key":"10.1016\/j.ymthe.2021.08.009_bib30","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1091581809359206","article-title":"Safety pharmacology and genotoxicity evaluation of AVI-4658","volume":"29","author":"Sazani","year":"2010","journal-title":"Int. J. Toxicol."},{"key":"10.1016\/j.ymthe.2021.08.009_bib31","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/1091581811403504","article-title":"Chemical and mechanistic toxicology evaluation of exon skipping phosphorodiamidate morpholino oligomers in mdx mice","volume":"30","author":"Sazani","year":"2011","journal-title":"Int. J. Toxicol."},{"key":"10.1016\/j.ymthe.2021.08.009_bib32","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1177\/1091581811403505","article-title":"Repeat-dose toxicology evaluation in cynomolgus monkeys of AVI-4658, a phosphorodiamidate morpholino oligomer (PMO) drug for the treatment of duchenne muscular dystrophy","volume":"30","author":"Sazani","year":"2011","journal-title":"Int. J. Toxicol."},{"key":"10.1016\/j.ymthe.2021.08.009_bib33","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1440-1789.2009.01028.x","article-title":"Exon-skipping therapy for Duchenne muscular dystrophy","volume":"29","author":"Nakamura","year":"2009","journal-title":"Neuropathology"},{"key":"10.1016\/j.ymthe.2021.08.009_bib34","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/jhg.2017.57","article-title":"Moving towards successful exon-skipping therapy for Duchenne muscular dystrophy","volume":"62","author":"Nakamura","year":"2017","journal-title":"J.\u00a0Hum. Genet."},{"key":"10.1016\/j.ymthe.2021.08.009_bib35","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s40265-016-0657-1","article-title":"Eteplirsen: First global approval","volume":"76","author":"Syed","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2021.08.009_bib36","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/nrneurol.2016.180","article-title":"Eteplirsen therapy for Duchenne muscular dystrophy: Skipping to the front of the line","volume":"12","author":"Dowling","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ymthe.2021.08.009_bib37","doi-asserted-by":"crossref","first-page":"14115","DOI":"10.1073\/pnas.1608520113","article-title":"Exon skipping of Fc\u03b5RI\u03b2 eliminates expression of the high-affinity IgE receptor in mast cells with therapeutic potential for allergy","volume":"113","author":"Cruse","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2021.08.009_bib38","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0145-2126(02)00343-0","article-title":"Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma\/leukemia; activation following aggregation of Fc\u03b5RI or Fc\u03b3RI","volume":"27","author":"Kirshenbaum","year":"2003","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ymthe.2021.08.009_bib39","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1083\/jcb.201311103","article-title":"Protecting the proteome: Eukaryotic cotranslational quality control pathways","volume":"204","author":"Lykke-Andersen","year":"2014","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.ymthe.2021.08.009_bib40","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1038\/s41594-018-0164-z","article-title":"Structural and molecular mechanisms for the control of eukaryotic 5\u2032-3\u2032 mRNA decay","volume":"25","author":"Mugridge","year":"2018","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ymthe.2021.08.009_bib41","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1034\/j.1600-0854.2001.020103.x","article-title":"Regulation of receptor tyrosine kinase signaling by endocytic trafficking","volume":"2","author":"Wiley","year":"2001","journal-title":"Traffic"},{"key":"10.1016\/j.ymthe.2021.08.009_bib42","doi-asserted-by":"crossref","first-page":"5715","DOI":"10.1038\/ncomms6715","article-title":"Oncogenic Kit signals on endolysosomes and endoplasmic reticulum are essential for neoplastic mast cell proliferation","volume":"5","author":"Obata","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2021.08.009_bib43","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1073\/pnas.96.4.1609","article-title":"Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis","volume":"96","author":"Longley","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2021.08.009_bib44","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/ced.12000","article-title":"Distinct signalling pathways for mutated KIT(V560G) and KIT(D816V) in mastocytosis","volume":"38","author":"Chan","year":"2013","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.ymthe.2021.08.009_bib45","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2144\/000113005","article-title":"Vivo-Morpholinos: A non-peptide transporter delivers morpholinos into a wide array of mouse tissues","volume":"45","author":"Morcos","year":"2008","journal-title":"Biotechniques"},{"key":"10.1016\/j.ymthe.2021.08.009_bib46","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.exphem.2005.11.015","article-title":"Establishment of a murine model of aggressive systemic mastocytosis\/mast cell leukemia","volume":"34","author":"Demehri","year":"2006","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.ymthe.2021.08.009_bib47","doi-asserted-by":"crossref","first-page":"eaao1690","DOI":"10.1126\/scitranslmed.aao1690","article-title":"A precision therapy against cancers driven by KIT\/PDGFRA mutations","volume":"9","author":"Evans","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2021.08.009_bib48","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.V90.4.1345","article-title":"Stem cell factor and hematopoiesis","volume":"90","author":"Broudy","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2021.08.009_bib49","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1056\/NEJMra1409760","article-title":"Mast cells, mastocytosis, and related disorders","volume":"373","author":"Theoharides","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2021.08.009_bib50","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1158\/1078-0432.CCR-04-2245","article-title":"Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation","volume":"11","author":"Antonescu","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2021.08.009_bib51","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1200\/JCO.2006.06.2265","article-title":"Molecular correlates of imatinib resistance in gastrointestinal stromal tumors","volume":"24","author":"Heinrich","year":"2006","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2021.08.009_bib52","first-page":"8024","article-title":"Gastrointestinal stromal tumors with exon 8 c-kit gene mutation might occur at extragastric sites and have metastasis-prone nature","volume":"7","author":"Ito","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.ymthe.2021.08.009_bib53","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1038\/sj.onc.1209639","article-title":"Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients","volume":"25","author":"Tamborini","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.ymthe.2021.08.009_bib54","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3324\/haematol.11339","article-title":"Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT","volume":"92","author":"Gleixner","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.ymthe.2021.08.009_bib55","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/2040620717721459","article-title":"Midostaurin: A novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis","volume":"8","author":"Gallogly","year":"2017","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.ymthe.2021.08.009_bib56","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1093\/nar\/gkw236","article-title":"The delivery of therapeutic oligonucleotides","volume":"44","author":"Juliano","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2021.08.009_bib57","doi-asserted-by":"crossref","first-page":"545","DOI":"10.15252\/emmm.201607199","article-title":"Delivery is key: Lessons learnt from developing splice-switching antisense therapies","volume":"9","author":"Godfrey","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymthe.2021.08.009_bib58","doi-asserted-by":"crossref","first-page":"E51","DOI":"10.3390\/biomedicines6020051","article-title":"Cell-penetrating peptides to enhance delivery of oligonucleotide-based therapeutics","volume":"6","author":"McClorey","year":"2018","journal-title":"Biomedicines"},{"key":"10.1016\/j.ymthe.2021.08.009_bib59","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1091\/mbc.E17-05-0288","article-title":"CRISPR-Trap: A clean approach for the generation of gene knockouts and gene replacements in human cells","volume":"29","author":"Reber","year":"2018","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.ymthe.2021.08.009_bib60","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40265-020-01267-2","article-title":"Golodirsen: First approval","volume":"80","author":"Heo","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2021.08.009_bib61","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40265-021-01512-2","article-title":"Casimersen: First approval","volume":"81","author":"Shirley","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2021.08.009_bib62","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s40265-020-01339-3","article-title":"Viltolarsen: First approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2021.08.009_bib63","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/mt.2012.264","article-title":"Exon skipping of hepatic APOB pre-mRNA with splice-switching oligonucleotides reduces LDL cholesterol in\u00a0vivo","volume":"21","author":"Disterer","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2021.08.009_bib64","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ijc.24052","article-title":"Modification of HER2 pre-mRNA alternative splicing and its effects on breast cancer cells","volume":"124","author":"Wan","year":"2009","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ymthe.2021.08.009_bib65","first-page":"Unit 3.23","article-title":"Generation, isolation, and maintenance of rodent mast cells and mast cell lines","volume":"Chapter 3","author":"Jensen","year":"2006","journal-title":"Curr. Protoc. Immunol."},{"key":"10.1016\/j.ymthe.2021.08.009_bib66","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.immuni.2013.04.007","article-title":"A truncated splice-variant of the Fc\u03b5RI\u03b2 receptor subunit is critical for microtubule formation and degranulation in mast cells","volume":"38","author":"Cruse","year":"2013","journal-title":"Immunity"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001621004032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001621004032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:06:16Z","timestamp":1761501976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001621004032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1525001621004032"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2021.08.009","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting KIT by frameshifting mRNA transcripts as a therapeutic strategy for aggressive mast cell neoplasms","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2021.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}